PHYSIOMICS PLC

• ◆

  5 officer resignations in last 12 months

  Multiple officers have left the board recently — see the People section for who.

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

IFRS

Reporting scope

Standalone (parent only)

Auditor

Moore Kingston Smith LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“Having undertaken this review, the Directors believe that the Company is adequately placed to manage its business and financing risks for the next twelve months from the date of approval of these financial statements. Accordingly, the Directors continue to adopt the going concern basis in preparing the annual report and accounts.”

Significant events

• “Total income increased 46% to £834,156 (2024: £570,561), meeting market expectations.”
• “The operating loss decreased 32% to £457,791 (2024: £670,816).”
• “Cash and cash equivalents at 30 June 2025 of £461,242 (30 June 2024: £191,072).”
• “Average total value of contract wins over FY24 and FY25 averaging over £1 million per annum, a 63% increase on the yearly average of the previous five years.”
• “Started new financial year ending 30 June 2026 (FY26) with approximately £594k of contracted revenue projected to be recognised within the year, a 19% year-on-year increase compared to FY24 carry forward.”
• “Appointment of Head of Quantitative Pharmacology and Data Science, Dr Mark Davies in November 2024 and Head of Biometrics, Jesse Thissen commencing in July 2025.”
• “Official launch of the Biometrics service line and announcement of the Company's first two Biometrics contracts worth £111k in aggregate.”
• “Expansion of services into new therapeutic areas: 50% of projects delivered in FY25 were in therapeutic areas outside of oncology, compared to an average of 5% over the previous three years.”
• “Diversification of client base: 31% of all contract awards in FY25 were from new clients, compared to 17% over the prior six years.”
• “Clinical Trial Approval of grant funded PREDICT-ONC trial with patient recruitment reaching 20% of the 100 patient target. The Company will receive £137,376 out of the total £570,651 grant award.”
• “Publication of three peer-reviewed scientific articles with Merck KGaA, Astellas Inc and Ankyra Therapeutics Inc.”
• “Post period end: Implementation of the Company's Personalised Dosing Software onto DoseMe's newly launched platform and expansion of the partnership with DoseMe.”
• “Post period end: Two additional contract awards, one with Numab Therapeutics and one with a large UK based biotech client.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

15

last 12 months

Capital events

2

last 24 months

Officers appointed

4

last 12 months

Officers resigned

5

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  +44.3%

  £543,250 → £784,005

• Cash

  +141.4%

  £191,072 → £461,242

• Net assets

  +145%

  £282,527 → £692,171

• Employees

  -9.1%

  11 → 10

• Operating profit

  +31.8%

  -£670,816 → -£457,791

• Profit before tax

  +31.6%

  -£668,754 → -£457,269

• Wages

  -7.2%

  £612,186 → £567,865

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers